Sumitomo Corporation Group Statement for UK Modern Slavery Act 2015 (FY 2020 Statement)

CytoReason and Summit Pharmaceuticals International Announce the Introduction of an AI Platform to One of Japan’s Top Pharmaceutical Companies

Sumitomo Corporation Group Statement for UK Modern Slavery Act 2015 (FY 2019 Statement)

Summit Pharmaceuticals International Corporation Invests in Luxna Biotech Co., Ltd. Possessing the Nucleic Acid Pharmaceutical Element Technologies

Signed a Contract for Sale of Stem Cells from Human Exfoliated Deciduous Teeth between Gene Techno Science Co., Ltd. and Summit Pharmaceuticals International Corporation.

Sumitomo Corporation Group Statement for UK Modern Slavery Act 2015 (FY 2018 Statement)

Establishment of a new cosmetics company

CytoReason and Summit Pharmaceuticals International Forge Commercial Alliance To Bring CytoReason’s Machine Learning Model of the Immune System for Drug Discovery & Development To Japanese Drug Makers

Sumitomo Corporation Group Statement for UK Modern Slavery Act 2015 (FY 2017 Statement)

Sumitomo Corporation Group Statement for UK Modern Slavery Act 2015 (FY 2016 Statement)

Successful Identification of Metabolite Differences in Urine between Healthy, Breast Cancer and Colorectal Cancer Groups

TRANSFER OF BUSINESS FROM SUMMIT PHARMACEUTICALS INTERNATIONAL TO SUMITOMO CORPORATION